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Abstract
Cholera is a major infectious disease, affecting millions of lives annually. In endemic areas, implementation of vaccination
strategy against cholera is vital. As the use of safer live vaccine that can induce protective immunity against Vibrio cholerae
O139 infection is a promising approach for immunization, we have designed VCUSM21P, an oral cholera vaccine candidate,
which has ctxA that encodes A subunit of ctx and mutated rtxA/C, ace and zot mutations. VCUSM21P was found not to
disassemble the actin of HEp2 cells. It colonized the mice intestine approximately 1 log lower than that of the Wild Type
(WT) strain obtained from Hospital Universiti Sains Malaysia. In the ileal loop assay, unlike WT challenge, 16106 and 16108
colony forming unit (CFU) of VCUSM21P was not reactogenic in non-immunized rabbits. Whereas, the reactogenicity caused
by the WT in rabbits immunized with 161010 CFU of VCUSM21P was found to be reduced as evidenced by absence of fluid
in loops administered with 16102–16107 CFU of WT. Oral immunization using 161010 CFU of VCUSM21P induced both IgA
and IgG against Cholera Toxin (CT) and O139 lipopolysaccharides (LPS). The serum vibriocidal antibody titer had a peak rise
of 2560 fold on week 4. Following Removable Intestinal Tie Adult Rabbit Diarrhoea (RITARD) experiment, the non-
immunized rabbits were found not to be protected against lethal challenge with 16109 CFU WT, but 100% of immunized
rabbits survived the challenge. In the past eleven years, V. cholerae O139 induced cholera has not been observed. However,
attenuated VCUSM21P vaccine could be used for vaccination program against potentially fatal endemic or emerging
cholera caused by V. cholerae O139.
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Introduction
V. cholerae is the causative agent of cholera which is a life-
threatening, acute secretory diarrhoeal disease, a major public
health problem that affects indigenous populations [1]. Despite
efforts taken to control V. cholerae infection [2,3], the global burden
of cholera is high, mostly affecting young children [4]. Though the
disease is controllable by clean water supply and sanitation
coverage [5], limiting the disease transmission persists as a
challenge to most developing countries [5,6]. An estimated
91,000 people die of cholera in endemic countries annually [7].
Cholera is associated with expression of CT encoded in the
ctxAB gene, which is acquired by V. cholerae from the filamentous
phage CTX [8]. The 27.2-kDa catalytic ctxA toxin is responsible
for activating the excretory chloride transport in the intestinal
crypt cells, while the ctxB helps in the internalization of the ctxA
[9]. Apart from the ctxAB toxin, the zonula occludens toxin (zot)
and accessary cholera enterotoxin (ace), located on a 4.5-kb central
core region of the CTX genetic element [10–13], were suggested
to cause probable diarrhoea symptom [11,14,15].
The cytotoxic activity of V. cholerae, which leads to actin
depolymerization of HEp-2 cells in vitro, is caused by RTX toxin
[16]. Although cholera is commonly considered to be a
noninflammatory secretory disease, RTX toxin produced by V.
cholerae O1 El Tor was demonstrated to contribute to the severity
of acute inflammatory responses [17]. Its operons exist as a four-
component type I secretion system (TISS) in the order rtxCABD
which plays a vital role as an activator and a transporter of the
toxin. The GD-rich repeated motif, rtxA, is the structural
component and also the crucial factor for the cytotoxicity of
RTX. RtxA requires rtxC, an acyl-carrier-protein-dependent acyl-
modification enzyme, for its conversion to active form [18].
Before 1992, cholera pandemic was exclusively caused by O1
serovars. But since 1992, a new non-O1 serovar the V. cholerae
O139, emerged [19,20]. Mysteriously, it acquired the ability to
overtake its predecessor strains, by establishing several cholera
endemics [21–23] with comparable clinical severity to El Tor O1
infection [24,25]. Rapidity of its spread was mainly due to lack of
acquired protective immunity in the population against it.
V.cholerae O139 has been undetected since 2005 [26]. Vaccine
candidate killed bivalent (O1 and O139) whole-cell oral cholera
vaccine is available [27]. Licensed WHO approved vaccines are
available for proection against cholera [3]. V. cholerae O139 could
become a major global pathogen again and development of new
vaccine is required. V. cholerae O139 attenuated vaccine strain has
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already been developed [28]. Oral killed bivalent vaccine (against
O1 and O139) is now WHO pre-qualified and has been
administered to hundreds of thousands of individuals in Asian
Bangladesh [27].
Lethal water-borne infection by V. cholerae that had caused a
devastating case fatality rate and potential pandemic emphasized
the need for adequate clean water supply and sanitation facility
[4]. In endemic-prone areas, pursuing the use of vaccine could be
an effective alternative option to control cholera cases [3,4,29]. A
number of important advances in genetic engineering led to a new
paradigm in cholera vaccine construction. In this regard, the
protection provided by the live attenuated vaccines is of particular
interest. The interaction between live attenuated vaccines and
immune system is much more effective than with killed, whole cell
vaccines [30]. Attenuated O1 vaccines CVD103 HgR, and Peru
15 have been evaluated in humans and are very safe and
immunogenic. .A live cholera vaccine against V. cholerae presented
several challenges [31], including mild diarrhoea experienced by
volunteers [32].
In the past several years, investigators at our laboratory
attempted to develop several live cholera vaccines against V.
cholerae O139. Recently, we have constructed a live VCUSM14
auxotroph vaccine candidate, shown to be a potentially efficient
attenuated cholera vaccine that secretes enzymatically inactive
ctxA subunit which is immunogenic yet safe [33]. The 7th amino
acid of the ctxA which is the arginine has been substituted with
lysine (R7K), and the 112th glutamate was substituted with
glutamine (E112Q). In this study, we used the VCUSM14 as a
parent vaccine for the construction of a new vaccine candidate. A
previous attenuated vaccine O139 strain was made and their
modifications have advantages over that previously developed
vaccine with less reactogenicity. As the virulence factor of
rtxCABD gene cluster of V. cholerae may be associated with residual
adverse properties displayed by certain attenuated cholera
vaccines [16], the toxin involved in the covalent cross-linking of
cellular actin activity, the RTX toxin, has been rendered non-
functional in VCUSM14. This safety issue is addressed in order to
provide enough assurance for its future use in humans. Besides
mutating the rtxC/A gene, the hemA gene was introduced
homogonously onto the chromosome. The resultant vaccine
candidate is designated as VCUSM21P. This designed vaccine
candidate synthesizes its own d-aminolevulenic acid (ALA) and
encodes the critical, non-toxic ctxA immunogen for protection
against cholera, and carries ace, zot and rtxC/A mutations. The aim
of this study was to modify VCUSM14, which already carried the
desired mutations in ctx, ace and zot, by mutating rtx and
replacing the mutated hemA by the wild-type allele. There is no
disease burden due to V.cholerae O139 induced cholera in the last
decade. In this investigation, we analyzed the potential use of
VCUSM21P as an attenuated vaccine candidate against V. cholerae
O139.
Materials and Methods
Bacterial strains, plasmids and growth media
The details of the description and origin of the bacterial strains
and plasmids used in this work are in Table 1. Luria – Bertani (LB)
broth was used for both liquid and agar media. Antibiotics were
added when appropriate at the following concentrations: poly-
myxin B (poly), 0.75 mg/mL; ampicillin (amp), 100 mg/ml;
Kanamycin (Kan), 50 mg/mL. Autotrophic strains were main-
tained in Luria-Bertani (LB) medium containing aminolevulenic
acid (80 mg/mL) supplementation with appropriate antibiotics.
Plasmids, based on the R6K origin of replication which requires
the product of the lpir gene for replication, were used for conjugal
mating. The plasmids were transferred into E. coli BW 20767 lpir
using heat shock method. For counter selection with sacB-
containing plasmids, LB without NaCl and with 10% sucrose
was used.
Animal
New Zealand White adult rabbits and BALB/c mice which
were bred in the Animal House, University Sains Malaysia (USM)
Health Campus, were used in this study. New Zealand White
Table 1. Bacterial strains and plasmids used in this study.
Strains or plasmids Description of strains or plasmids Source
Strains
E. coli BW 20767 lpir RP4 2tet: mu-1kan::Tn7integrant leu 63::IS10 rec A1 cre(510 hsdR17
end A1 Zbf-5 uid) (DMluI): pir thi
Gift from Dr. William Metcalf, University of Illinois
WT V. cholerae O139 isolated from a patient in HUSM Hospital University Sains Malaysia
VCUSM14 V. cholerae O139 ALA auxotroph derived from VCUSM2; has 1 copy
of Dctx operon; 1 copy of Dctx operon::DaphA; DhemA
Universiti Sains Malaysia
VCUSM20 V. cholerae O139 ALA auxotroph strain that was constructed from
VCUSM14. It has 1 copy of Dctx operon, 1 copy of Dctx
operon::DaphA, rtxC::aphA and DhemA genes.
This study
VCUSM21 V. cholerae O139 ALA auxotroph strain that was constructed from
VCUSM20. It has 1 copy of Dctx operon, 1 copy of Dctx operon::DaphA,
DrtxC/A and DhemA genes.
This study
VCUSM21P V. cholerae O139 ALA non-auxotroph strain that was constructed from
VCUSM21. It has 1 copy of Dctx operon, 1 copy of Dctx operon::DaphA,
DrtxC/A and hemA genes.
This study
Plasmids
pWM91-rtxC::aphA pWM91 with rtxC::aphA fragment USM
pWM91-DrtxC/A pWM91 with DrtxC/A fragment USM
pCVD-hemA/M pCVD442 with hemA-hemM fragment USM
doi:10.1371/journal.pone.0081817.t001
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adult male rabbits (weighing 2.0–2.5 kg at the onset of the
experiments) were used only if they were healthy and showed no
evidence of diarrhoeal disease during the time period. All
procedures involving the use of animals had the approval of the
Animal Ethics Committee (AEC), USM. The institution’s law on
the care and use of laboratory animals was followed.
Construction of auxotropic vaccine strains: VCUSM20 and
VCUSM21
To construct rtxC mutation in VCUSM14, VCUSM14 was
conjugated with E. coli BW 20767 lpir carrying pwm91 rtxC::aphA.
The conjugation was done at 37uC incubation on LB agar
supplemented with ALA. After 5 hours, bacteria were transferred
from the plate to LB broth and suspended. The cell suspension was
diluted, and then spread on LB agar supplemented with ALA and
consisting of Kan/Amp/Poly, which was used to obtain co-
integrate/transconjugants and to non-counter-select the E. coli BW
20767 lpir donor strain and VCUSM14. The plates were
incubated overnight at 37uC for 12–16 hours. Colonies/transcon-
jugants from the plates were selected and confirmed by antibiotic
resistance and also PCR. The confirmed transconjugant was
suspended in NaCl free LB broth with 10% sucrose and with
80 mg/ml ALA added and incubated at 21–25uC for 12–16 hours.
The suspension was plated at various dilutions on NaCl free LB
agar with Kan, , supplemented with ALA and solidified with
sucrose (10%, w/v) and incubated at 21–25uC. Selection of the
desired clone was based on its ability to be SucR/KanR/AmpS/
PolyR, inability to grow without ALA supplement and ability to
produce yellow colonies on Thiosulfate-Citrate-Bile-Sucrose Agar
(TCBS) supplemented with ALA. The constructed strain was
designated as VCUSM20 and and the rtxC deletion was further
confirmed by performing PCR using primers rtxC-R1 (59-
GGTGGCCAGTGGAATCTTCCA-39) and rtxC-F1 (59-
AAAGTCGGTATTGCGGCACGC-39). The above procedure
was followed for the construction of DrtxC/A mutant but with
modification. E. coli BW 20767 lpir carrying pwm91 DrtxC/A was
conjugated with VCUSM20. Clone counter-selection and elimi-
nation of the E. coli donor strain and VCUSM20 were performed
by plating on LB Amp/Poly agar plate without adding Kan.
Desired clone selection was based on its ability to be SucR/KanS/
AmpS/PolyR, not to grow without ALA supplement and produce
yellow colonies on TCBS agar supplemented with ALA. The
obtained strain was named as VCUSM21. This strain construct
was was screened with the similar primers as mentioned above,
rtxC-R1 and rtxC-F1, for confirmation. List of plasmids that were
used in the present study is given in Table 2.
Construction of non-auxotropic vaccine strains:
VCUSM21P
In order to construct a vaccine candidate from VCUSM21 that
could synthesize its own ALA, the WT hemA gene was deleted and
replaced with the DhemA gene. Construction was performed as
mentioned above with modification. For VCUSM21P construc-
tion, E. coli BW 20767 lpir carrying pCVD hemA/M was used as
donor strain and VCUSM21 were used as recipient strains.
Bacterial conjugation was done on LB agar supplemented with
ALA and merodiploids were obtained from LB agar with Amp/
Poly but without ALA supplement, allowing selection for clones
that could synthesize their own ALA. The recombinant strains
were derived directly by growing the merodiploid in LB broth
lacking NaCl with 10% sucrose but without ALA and plated as
mentioned above at various dilutions on LB agar, without NaCl,
and solidified with sucrose (10%, w/v), but without ALA
supplement. Through this selection process, cells which still
remain as hemA mutant were not able to grow in the broth
medium and on the plates, thus not selected. The obtained clones
were further confirmed by testing their ability to be SucR/KanS/
AmpS/PolyR, ability to grow without ALA supplement and ability
to produce yellow colonies on TCBS agar. The construction was
confirmed successful only if the clone could synthesize its own
ALA, which is necessary for hem biosynthesis. Confirmation was
done by testing the clone ability to grow on LB agar without ALA.
The ALA producing clone was designated as VCUSM21P.
Colonies were serologically confirmed as V. cholerae O139.
GM1 enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay analysis was performed to
determine the inactivated CT, CT B subunit and CT A subunit in
VCUSM21P. Briefly, ELISA plates (MaxiSorp; Nunc) were
coated with 100 ng/well of commercially available type lll GM1
ganglioside in 60 mM carbonate buffer (pH 9.6) at 4uC. Com-
mercially available cholera toxin was used as a standard with the
starting concentration of 100 ng followed by 1:2 dilutions. Culture
was prepared by incubating 16106 colony forming unit (CFU) of
Wild Type (WT) or VCUSM21P cells in 10 ml LB broth for
18 hours. 100 ml of each culture supernatant was added into the
wells. As primary antibody, rabbit anti-cholera toxin polyclonal
antibodies, rabbit polyclonal anti-CTB antibody and rabbit
polyclonal anti-CTA antibody (1:2000 diluted in PBS), were used.
Whereas, anti-rabbit IgG antibodies conjugated with HRP (1:3000
diluted in PBS) were used as secondary antibodies. To complete
the reaction, the wells were added with 2,29-azino-bis(3-ethyl-
benzthiazoline-6-sulphonic acid) (ABTS). Reaction was allowed to
take place for 30 minutes in the dark and stopped before readings
were taken using Multiskan EX microtiter plate reader at 405 nm
with reference to 495 nm.
Cytotoxicity Assays
HEp-2 cells were seeded into 24-well tissue culture plate at
16105 cells per well in RPMI medium 1640 with 10 mM HEPES
buffer, 2 mM glutamine, 10% fetal calf serum and supplements
(without antibiotics) as described by Lin et al. [16]. A subconfluent
monolayer of HEp-2 cells in a 24-well tissue culture plate was
infected with VCUSM21P or WT at a multiplicity of infection
(MOI) of 100. PBS was added to the monolayer of HEp-2 cells as a
control. The plate was incubated in 5% CO2 at 37uC for 1 h
before viewing live cells under an inverted microscope. Cytotoxic
activity was identified if cell rounding of live cells became visible.
Mouse Colonization Assay
Eight 3–5-days-old BALB/c mice were divided into four groups
and kept fasting by separating them from their mothers 1 hour
prior to performing the mouse colonization assay as described
before by Angelichio et al. [34]. Mice from the first group were
inoculated with VCUSM21P strain, the second and third were
inoculated with VCUSM20 and VCUSM21 respectively, and the
fourth group was inoculated with WT. The inoculation was
performed intragastrically, whereby 16106 cells of strain in 50 ml
ice-cold NS was fed to the mice by 21 G gavage tube inserted
1 cm deep into the oesophagus. After 16–18 h, all mice from each
group were euthanized using chloroform, and their gut were
excised before placing into 15 ml centrifuge tube containing 5 ml
of sterile LB-20% v/v glycerol. They were then transferred into
sterile potter homogenizer and homogenized in LB-20% v/v
glycerol. The presence of viable vibrios from the mice intestine
were assessed by serially diluting the homogenates and plating
100 ml of each diluted suspension onto LB agar containing Poly
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(for WT and non-autotrophic mutant) or LB agar containing Poly,
supplemented with ALA (for autotrophic mutants). The plates
were incubated for 16 h at 37uC. The numbers of viable tested
strains colonizing the intestine were quantified by counting
subsequent colonies after 16 hours of incubation.
Immunization of rabbits
Four New Zealand White rabbits were used for vaccine
administration as performed by Thungapathra et al. [35] with
modifications. Prior to vaccination, the rabbits were orally
administered twice (with an interval of 2 days) with 125 mg/kg
of Metronidazole and 164 mg/kg of Sulfaquinoxaline. The rabbits
were fasted 24–36 hours before the first vaccination but water was
given ad libitum. They were anaesthetized with an intramuscular
injection of ketamine (35 mg/kg), Xylazine (4 mg/kg) and
Acepromazine (1 mg/kg). Before vaccinating the rabbits with
VCUSM21P, they were intravenously administrated with Cimet-
idine (50 mg/kg) to inhibit HCl secretion and followed by
NaHCO3 administration to neutralize their gastric pH. Rabbits
were given a first vaccination with 161010 CFU of VCUSM21P
in 10 ml LB broth, on day 0. To inhibit the peristaltic movement,
1 ml of morphine (10 mg) was injected intra-peritoneally before
they were returned to their cages. The second vaccination was
administered to the rabbits on day 14.
Assessment of vibrios shedding after immunization
To assess the excretion of vibrios or shedding of challenge
vibrios in coproculture, briefly, rectal swab was performed daily
after first and second vaccination, up to 5 days. The rectal swab
was incubated at 37uC for 5–6 h in alkaline peptone water [APW;
peptone 1% (wt/vol), NaCl 1% (wt/vol)]. 100 ml of the enriched
culture was then streaked on TCBS and incubated at 37uC for
16 hours. Any appearance of thin-edged yellow colonies on TCBS
agar was recorded.
Serology
The pre-immune sera samples were collected from the ear vein
of the rabbits before immunization. The post-immune sera
collections were done at an interval of 7 days, up to 4 weeks. All
collected serum samples were stored at 220uC until tested for the
presence of vibriocidal antibodies, as well as for the specific CT
and O139 LPS antibodies.
Antibody assays
CT and O139 LPS -specific antibody titres in serum were
determined by performing ELISA. The ELISA plates were coated
with either commercially available CT or O139 LPS extracted in
the laboratory for anti-CTAB IgG or IgA, and anti-LPS IgG or
IgA detection, respectively. Briefly, 96-well microtiter plates
(Maxisorp; Nunc) were coated overnight at 4uC with 50 ng/well
of either CT or 50 ng/well of O139 LPS in carbonate buffer
(pH 9.6). Serum samples were diluted to 1:10–1:1280 in PBS and
used as the primary antibody. The diluted sera were suspended
and incubated in the presence of anti-rabbit IgG-HRP (100 ml;
1:5000 in PBS) as the secondary antibody at 37uC for 30 min or
IgA-HRP (100 ml; 1:3000 in PBS) at 37uC for 1 h. To complete
the assay, 100 ml of ABTS (1 mg/ml) was added into the wells and
subsequently incubated at 37uC in the dark for 30 min. Plates
were read at 405 nm with reference to 495 nm using a Multiskan
EX microtiter plate reader. The antibody titer is defined as the
highest dilution that gave an optical density (OD) greater than that
of the preimmune serum.
Vibriocidal antibody assay
Sera from rabbits immunized with VCUSM21P were assayed
for vibriocidal antibodies against CIR134 strains of V. cholerae
following an assay protocol as described previously by Attridge
et al. with modification [36]. Serum was inactivated at 56uC for
30 min. In the wells of 96-well microtiter plates, the inactivated
serum was serially diluted in PBS (1:10 to 1:20480). 50 ml of a
chilled suspension comprising the indicator bacteria (CIR134 in a
final concentration of 16105 cells/ml) and fresh commercially
available normal rabbit serum (20% v/v) as a source of
complement factor was then added into the wells. After incubation
at 37uC for 60 min, the suspensions from the microtiter plates
were plated on LB/polymyxin plates and incubated at 37uC for
16 h. Vibriocidal titer was defined as the highest serum dilution
causing 100% bacterial killing as compared to the pre-immune
sera.
Protective efficacy in RITARD
RITARD (Reversible Intestinal Tie Adult Rabbit Diarrhoea)
assay was performed on the non-immunized and immunized
rabbits by the method of Rusell et al. [37]. In RITARD model, the
caecum was ligated as close as possible to the ileocaecal junction
following application of a reversible knot tie at the ileum,
approximately 10 cm away from the ileocaecal junction. Rabbits
were challenged with 16109 CFU WT which was injected into the
Table 2. Primers used in this study with their sequences, annealing temperature and functions.
Primer Sequence 59 — 39 TA 6C Function
SacBF2 ATGAACATCAAAAAGTTTGCAAAA 58 Amplification of sacB gene in merodiploids and to confirm the elimination of
suicidal plasmid backbone in V. cholerae
SacBR TTATTTGTTAACTGTTAATTGTCC 58 Amplification of sacB gene
KanFse-2F AGCGGCCGGCCGCTTACATGGCGATAGCTA 56 Amplification of aphA cassette in V. cholerae
KanFse-R ATAGGCCGGCCTCAGAAGAACTCGTCAAGA 60 Amplification of aphA
RtxC F TTATCAGAGATGGCAGCACC 66 Amplification of rtx, DrtxC/A and rtx::aphA genes in V. cholerae
RtxC R CTTGTCCACCGCTGTAGCCT 66 Amplification of rtx, DrtxC/A and rtx::aphA genes in V. cholerae
VHAF ATGTCTTTGCTTGCCATTGG 56 Amplification of hemA and DhemA genes in V. cholerae
VHAR2 GTTCAGATCGTCAAGACCTA 56 Amplification of hemA and DhemA
TA annealing temperature.
doi:10.1371/journal.pone.0081817.t002
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jejunum 10 cm distal to the stomach. Control group of animals
was included. The knot was removed 2 hours after administration
of WT. All the rabbits undergoing RITARD experiment were
observed every 6 h for clinical signs of infection such as diarrhoea
symptoms or death, up to 5 days. Shedding of vibrios in faeces was
monitored. The animals were euthanized with an intravenous
injection of sodium pentabarbitone on day 6 and microbiological
testing was performed by collecting mucus or fluid from the
intestine and plating on TCBS.
Reactogenicity studies in ligated ileal loop model
The surgical procedures employed in this study have been
described previously by Thungapathra et al. with modifications
[35]. The rabbits were kept fasting for 24 hours prior to the
surgery. Anesthesia was induced as described in immunization.
Following anesthesia, an incision was made along the linea alba of
the abdominal wall. The ileum was exposed and ligation was
performed approximately 10 cm away from ileocaecal junction.
Five cm long loops were ligated on the small intestine, leaving
1 cm loops between them. 1 ml sterile NS was injected into the
lumen of the control loops. Others were inoculated with 1 ml of a
suspension of VCUSM21P or WT strains in NS containing
approximately 16106 and 16108 CFU/ml. After 18 h, rabbits
were euthanized to assess the reactogenicity. Reactogenicity was
described in fluid accumulation ratio, FA, the ratio of fluid in the
intestinal loop (milliliters) to length of the loop (centimeters).
Results
Construction of vaccine strains
The vaccine candidate VCUSM20 was successfully obtained by
introducing the rtxC::aphA gene into the chromosome of
VCUSM14 via suicide plasmid integration into the chromosome
and subsequent sucrose counterselection (Figure 1). Using a similar
technique, VCUSM21 was constructed by introducing DrtxC/A
gene into the chromosome of VCUSM20 and replacing the
rtxC::aphA gene (Figure 1). The mutants were successfully
confirmed not to carry the native rtxC/A gene by PCR. Finally,
the construction was completed by removing the mutated hemA
gene and replacing it with hemA gene of the WT that could code
the functional glutamyl-tRNA reductase (Figure 2). The selected
clone was confirmed to be able to grow on all test plates and
produced the expected bands after PCR amplification. The
mutant is a SucR/KanS/AmpS/PolyR strain and it is able to
produce yellow colonies on TCBS agar. The new vaccine
candidate, VCUSM21P, is a ctxA, ace, zot and rtxC/A mutant
that has lost its parent auxotropic characteristic, its dependency on
ALA supplement for survival.
Glutamyl-tRNA reductase production and ALA test
Production of glutamyl-tRNA reductase is required for ALA
biosynthesis, and consequently for hem biosynthesis in VCUSM14.
It has limited generation without ALA supplement due to its
inability to encode glutamyl-tRNA reductase. In order to
determine whether VCUSM21P has similar function in encoding
glutamyl-tRNA reductase as the WT, VCUSM21P and the WT
strains were grown in LB broth and on LB agar plate without ALA
supplement. VCUSM20 and VCUSM21 strains were also
included in this test. Both VCUSM20 and VCUSM21 had
growth impairment in LB broth, and neither of them survived on
LB agar without ALA supplement. On the contrary, VCUSM21P
and the WT strain were surviving and growing in LB broth/on
agar without ALA supplement, confirming VCUSM21P indepen-
dency on ALA supplement for its survival or growth. Replacement
of the mutated hemA gene with its homologous WT gene resulted
in functional glutamyl-tRNA reductase encoded by VCUSM21P,
as the WT cells could, and ultimately lead to the synthesis of hem
within its cells.
Cytotoxicity assay
To evaluate the cytotoxicity of the constructed vaccine
candidate, HEp-2 cells were infected with VCUSM21P and WT
infected cells were included for comparison. Cytotoxic effect is
appreciated/recognized as rounding up of infected cells due to
depolymerization of cytoskeleton actin. Because the cytotoxic
activity can be easily monitored by microscopic analysis of HEp-2
cell line, the ability of the vaccine candidate to depolymerize actin
was discerned by observing the infected HEp-2 cells under an
inverted microscope. VCUSM21P infected cells failed to demon-
strate cell rounding activity as shown in Figure 3C, indicating
absence of cytopathic effects on HEp-2 cells. By contrast, WT
exhibited massive cell rounding of infected HEp-2 cells indicating
its cytotoxic effect on them (Figure 3B). The absence of cell
rounding, compared with the cytotoxic activity created by the WT
on the HEp-2 cells, suggests that VCUSM21P has lost the
fundamental role in the actin depolymerization.
Non-toxic CT production
The production of immunogenic CT which consists of five
identical B subunits and a non-enzymatically active A subunit by
VCUSM21P was measured by GM1 ganglioside-binding ELI-
SA.Detectable amounts of CT were present in the culture broth of
WT, as well as VCUSM21P, as shown in Figure 4 & Table 4. WT
strain produce native CT, but the vaccine strain produces
inactive/mutant CT. The ace, zot, ctxA and rtxC/A mutant was
confirmed to encode the non-toxin CT successfully, but the
production was more diminished compared with WT. The
rationale for the diminished amount is not known. It is possible
that several genomic alterations that VCUSM21P has undergone
during its creation through the homologous recombination or
sucrose counter-selection could be the explanation for the
reduction in CT gene expression and CT production. Alterna-
tively, the explanation may well be due to the mutation of ctxA
found at the region of ctx operon.
Colonization
The colonization ability of VCUSM20, VCUSM21 and
VCUSM21P in the infant mice intestine was assayed to test the
capability of these strains to attach to the eukaryotic cell surface of
the host prior to induction of an immune response. Interpretation
of the data obtained, expressed in terms of average CFU recovered
after inoculating 16106 CFU, from infant mice intestine showed
that colonization of both VCUSM20 and VCUSM21 did not take
place in the infant mice bowel. Nevertheless, VCUSM21P
colonized exceptionally well, an average of 1.556106 CFU of
VCUSM21P was recovered from the infant mice intestine.
However, the average number of recovered cells of this vaccine
candidate was found to be less when compared to viable cells
recovered from mice inoculated with the WT. The ability of
VCUSM21P to encode for glutamyl-tRNA reductase, and thus to
synthesize ALA, has dramatically improved the colonization
ability of it. We concluded that the presence of hemA mutation
in its parent vaccine caused a remarkable effect on the intestinal
colonization of V. cholerae in mice. VCUSM21P is a good colonizer
of the small intestine and preferred vaccine candidate for
vaccination against cholera due to its potential means to stimulate
effective immune response compared with its respective parent
strains.
Safe Live Attenuated Cholera Vaccine
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e81817
Reactogenicity study
In order to assess whether this newly constructed vaccine is
causing reactogenicity, we analyzed the fluid accumulation ratio
(the mean fluid (ml)/length (cm) ratio of loop) of the WT in
parallel with VCUSM21P by ileal loop assay. As indicated in
Figure 5, there was an increase in the fluid accumulation ratio in
loops injected with 16106 and 16108 CFU of WT. These
characteristics would appear to correlate with the symptoms of
acute cholera, i.e. having frequent loose or liquid bowel
movements. Differing to that anticipated for the WT,
VCUSM21P did not show any sign of hemorrhage or reactoge-
nicity, FA ratio in both 16106 and 16108 CFU of VCUSM21P
administrated loops were $0 (Figure 5). Inability of VCUSM21P
to induce any fluid accumulation or potentially diarrhoea could be
principally due to its non-functional CTA that could not influence
the intracellular cAMP activation. Moreover, the positive effects
on fluid accumulation in intestinal loops could be greatly
attributed to the absence of ace, zot, rtxC/A and ctxA toxin activity
as a whole.
Antibody responses in serum following oral
immunization
Antibodies against CTAB and LPS O139. As can be seen in
Table 3, all the immunized rabbits were found to have antibodies
against CTAB and LPS O139 in their sera. Seven days after the
first immunization, a low geometric mean titer (GMT) of anti-
CTAB IgG/IgA and anti-LPS IgG/IgA were detected in all sera
of immunized rabbits, as compared to the basal titer. This proves
the very early immune responses induced by the administered
vaccine. GMT records of the following weeks showed that all the
immunized rabbits kept producing rising antibodies of O139 LPS
IgG/IgA and anti-CTAB IgG/IgA. The majority of immunized
rabbits were found to acquire the highest level of protection
against CT or O139 LPS on week 3 or 4, as evidenced from their
serum anti-O139 LPS IgA titer having their peaks at week 3, and
anti-O139 LPS IgG and anti-CTAB IgG/IgA titers having at
week 4. The geometric mean fold increase from baseline of O139
LPS IgG induced by VCUSM21P on week 1 was statistically
significantly (p#0.05). Immunological study has confirmed that
VCUSM21P is capable of inducing humoral immune responses
against CT and O139.
Figure 1. Diagram of the auxotrophic strains, VCUSM20 and VCUSM21, construction. The diagram is a schematic representation of
mutation introduced at the rtx gene cluster on VCUSM14 (A) and VCUSM20 (B) chromosomes. It shows the double copies of Dctx operon, DhemA-
hemM genes and rtxC::aphA genes in VCUSM20, and rtxC::aphA replaced with DrtxC/A in VCUSM21. Gene designations: DctxA operon, mutation in CT
A subunit with complete deletion of accessory cholera enterotoxin (ace) and zonula occludens toxin (zot); repeat-in-toxin (rtx); bla, b-lactamase; sacB,
Bacillus subtilis counterselectable marker sacB which encodes levan sucrase.
doi:10.1371/journal.pone.0081817.g001
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Vibriocidal antibodies. Furthermore, VCUSM21P was
found to stimulate an effective antibacterial antibody response
capable of killing vibrios in all rabbits as the detected vibriocidal
antibodies were higher in all post-immune sera than that of the
pre-immune sera (Table 3). An elevated vibriocidal antibody titer,
320 GMT, was recorded in the first week, indicating the level of
protection provided by VCUSM21P against cholera at the very
early stage following immunization. At week 2, VCUSM21P
elicited a ,538-fold increase in vibriocidal antibody titer
compared with that of the basal titer, 10 GMT. The antibodies
continued to rise to 1810 GMT in the following week. The highest
level of vibriocidal antibody, 2560 GMT, was detected at week 4.
All immunized rabbits were confirmed to develop the preferred
protection against cholera after vaccination using VCUSM21P.
Bacterial shedding following the oral vaccination
Shedding of vibrios after vaccination, an indication of the
intestinal colonization and multiplication of the vaccine candidate
in the intestine, by the rabbits was assessed from their rectal swab,
which were enriched in APW and later grown on TCBS agar
plate. Among the 4 rabbits, two of them did not shed vibrios after
the first immunization, but shedding by the other two rabbits
lasted for 1–2 days, representing intestinal passage. After the
second immunization, shedding of vibrios was not found in any of
the rabbits.
Figure 2. Diagram of the prototrophic vaccine candidate,
VCUSM21P, construction. The diagram is a schematic representa-
tion of DhemA mutation removed from VCUSM21 chromosome, and
replacing it with the native hemA gene from V. cholerae O139. It shows
the double copies of Dctx operon, DrtxC/A, and hemA/M genes in
VCUSM21P. Gene designations: as Figure 1.
doi:10.1371/journal.pone.0081817.g002
Figure 3. Inverted microscopy reveals morphological changes
on HEp-2 cells after infection with WT (B) and VCUSM21P (C),
at a magnification of640. As control, HEp-2 cells in PBS (A) were
included in the cytotoxic assay. HEp-2 cells were incubated for 1 hour
with WT and VCUSM21P cells at multiplicity of infection (MOI) of 100. B
shows rounded HEp-2 cells indicating cytotoxic effects. A and C show
HEp-2 cells with normal morphology indicating absence of cytotoxicity.
doi:10.1371/journal.pone.0081817.g003
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Protection provided by immunization/Protection
obtained from immunization
Challenge study using RITARD model. In the RITARD
experiment, the immunized animals were challenged with freshly
cultured 16109 CFU of WT strain in sterile saline via intradou-
denal injection, to assess the immunity induced by VCUSM21P.
The immunized-animals which were examined twice daily up to 5
days, had a positive clinical outcome, without any symptoms of
diarrhoea or mortality. Microbiological examination for the
presence of WT colonies on TCBS agar plate revealed that after
five days, WT strains were not found in the intestine of immunized
Figure 4. Cholera toxin production by vaccine candidate VCUSM21P and WT strain. Values are expressed as mean6 standard deviation.
doi:10.1371/journal.pone.0081817.g004
Table 3. Antibodies titers of rabbits immunized with VCUSM21P.
Vaccine candidatea´ Antibody GMT Pre-immune Week GMT (SD) g˘: Post-immune p-Value
VCUSM21P CTBA IgG 10 1 11.89 (5) 0.317
2 23.78 (32.02) 0.102
3 95.14 (60) 0.066
4 113.14 (46.19) 0.063
CTBA IgA 10 1 14.14 (5.77) 0.157
2 33.64 (10) 0.059
3 47.57 (20) 0.059
4 135.62 (40) 0.059
O139 LPS IgG 10 1 40 (0) 0.046*
2 226.27 (0) 0.059
3 755.08 (240) 0.059
4 883.80 (300) 0.059
O139 LPS IgA 10 1 28.28 (11.55) 0.063
2 47.57 (20) 0.059
3 95.14 (40) 0.059
4 67.27 (20) 0.059
Vibriocidal 10 1 320 (0) 0.046*
2 538.17 (452.55) 0.066
3 1810.19 (739.01) 0.063
4 2560 (0) 0.046*
a´Immunization with 161010 CFU of vaccine candidates.
g˘Geometric Mean Titer (GMT) antibody in sera of four animals.
Significant difference between the pre-immunization and post-immunization levels is shown by * (p#0.05, Wilcoxon signed rank test).
GMT is defined as ‘‘the ‘n’th root product of ‘n’ numbers’’, (a1a2…an)
1/n.
doi:10.1371/journal.pone.0081817.t003
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rabbits. As reported previously [38] and found in this study, 100%
of the non-immunized rabbits had a fatal clinical outcome
following infection with WT at a dose of 16109 CFU, where
they experienced severe diarrhoea and eventually did not survive.
Reactogenicity in ileal loop assay. An in vivo ileal loop
assay, as described above, was used to estimate the protection that
VCUSM21P could provide against WT. To determine the
capacity of cholera toxin and also other toxins to induce
reactogenicity in vaccinated rabbits, the presence of fluid was
assessed in the intestinal loops that were challenged with different
CFUs of WT. 3 weeks after second immunization, 16102–
16108 CFU of WT were injected into the loops. As mentioned
above, in non-immunized rabbits, 16106 and 16108 CFU of WT
infection caused extensive fluid accumulation in the intestinal
loops. However, in immunized rabbits, only the loops challenged
with 16108 CFU WT had fluid present, but not in loops
challenged with 16106 CFU. This signifies a reduction of the
elevated cAMP level in the intestinal mucosal cells following WT
challenge in immunized rabbits. In others, loops receiving 16102
to 16105 and 16107 CFU of WT, were also found to be
protected; they had no fluid accumulation.
Discussion
Cholera is the vaccine-preventable killer of adult and children in
the developing world. Understanding of V. cholerae virulence factors
has increased greatly during recent years but remains incomplete.
The mechanisms that regulate reactogenicity of V. cholerae are
remarkably conserved within the ctx operon of the phage genome
that resides on its chromosome. However, few studies have shown
that the other virulent proteins might be contributing to, or are
regulating, residual reactogenicity in the host. The isolation of V.
cholerae WO7, a O1 serovar, from patients with diarrhoea indicated
that virulent ctxA, zot, and ace genes were not the only genes
involved in gastrointestinal disease as WO7 is devoid of all these
genes of phage belongings [39]. Previous studies also have shown
that vaccinees were experiencing mild diarrhoea after vaccination
with live O1 V. cholerae vaccine candidate that were ctx, zot and ace
mutant [32].
Besides toxins produced by the genes belonging to the CTXW
lysogen, the repeat-in-toxin (RTX) exoprotein could have a
significant role in inducing diarrhoea in host infected with lethal
vibrios. RTX toxin was suggested to contribute to the emergence
of pathogenic non-O1/non-O139 strains [40]. Many RTX
mutants of microbial species have been described that exhibit a
defect in or loss of cytotoxic activity [16,41,42]. This is due to the
inability of the defective RTX protein to bind actin and catalyze
the cross-linking reaction that leads actin monomers into dimers,
trimers, and higher multimers. According to Lin et al., the
cytotoxic activity is not caused by ctxAB, zot, or ace genes, but only
by the rtx gene cluster [16]. Moreover, RTX toxin produced by V.
cholerae O1 El Tor was demonstrated to contribute to the severity
of acute inflammatory responses [17] associated with interleukin
(IL)-6 and murine macrophage inflammatory protein (MIP)-2,
suggesting that the toxin induces cellular events that promote
inflammation. This toxin also promotes the production of
proinflammatory substances such as IL-1, TNF, nitric oxide, and
eicosanoids [43]. The above description and suggestions link RTX
toxin to gastrointestinal inflammation.
As safety is one of the main concerns for attenuated live
vaccines, in this work, we extended the safety studies of the
VCUSM14 vaccine candidate against V. cholerae O139. This was
performed by constructing a new vaccine candidate by disrupting
the rtxC/A gene on chromosome of VCUSM14. To confirm that
RTX toxin lost its activity due to mutation, we analyzed the ability
of VCUSM21P to produce cell rounding of HEp-2 cell line.
Mutation of both the rtxA and rtxC genes completely abolished the
cell rounding activity of O139 strain [40]. Deletion of a
chromosomally encoded rtxC/A in VCUSM21P led to a reduction
or absence of cytoxicity to the HEp-2 cells; it exhibited defective
cell rounding activity. This gained insight suggests that
VCUSM21P has lost the depolymerization of actin cytoskeleton.
Based on this observation, it is suggested that this new vaccine
could play a role in intervening the cytotoxin mechanism, which
may possibly be associated with factors contributing to the
development of mild diarrhoea.
In previous studies, we have designed attenuated VCUSM2 and
VCUSM14 vaccine candidates; both attenuated vaccines are
metabolic auxotroph recombinant which requires exogenous
supplement of ALA for survival. Unlike its parent strain
VCUSM2, which has impairment in encoding for glutamyl-tRNA
reductase, VCUSM14 has additional mutations at the ctx operon,
where the double copies of ace and zot genes were removed and its
ctxA, in dual copies, has been rendered non-virulent.
In VCUSM14, ALA supplement is required for the hem
synthesis and it is unable to grow without ALA; hemA deficiency
obviously affected the cell growth as hem is essential for many
cellular processes. In this study, due to inability of VCUSM14 to
encode ALA in vivo, the vaccine candidates derived from it were
found to have reduced colonization ability in the infant mouse
intestine. A reduction in the number of colonizing cells was also
reported in our previous studies, where the auxotrophic VCUSM2
did not colonize as the WT [38]. For the induction of effective
Table 4. Cholera toxin, CT A and CT B production by vaccine
candidate VCUSM21P and WT strain.
Strain Mean concentration in culture supernatant (ng/ml)
CT A CT B CTAB
WT 146.26 174.40 180.47
VCUSM21P 18.12 141.18 20.03
doi:10.1371/journal.pone.0081817.t004
Figure 5. Fluid accumulation ratio in loops of unvaccinated
rabbits.
doi:10.1371/journal.pone.0081817.g005
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immune responses, successful and efficient infection mechanism is
required. As colonization, a process of breaching mucosal barriers
by the live vibrios and their attachment to receptors of epithelial
cells, is required to initiate infection, improvement in colonization
capacity of VCUSM14 prototype was essential.
Therefore, in this study, besides mutating the rtxC/A by allele
replacement technique, the probable inability of VCUSM14 to
induce high and sustained titers of antibodies against cholera was
addressed. The WT hemA gene was introduced in VCUSM21P.
Analysis of mice colonization assay revealed a significant increase
in colonization ability of VCUSM21P compared to that of
VCUSM21. Given that the VCUSM21 did not survive after
overnight incubation without ALA supplement on LB agar, and
correlating this with the mouse colonization assay, it was
concluded that due to inability to synthesize ALA, VCUSM21
cells could not survive without ALA supplement in the intestine
whereas the VCUSM21P could survive VCUSM21 could still
mimic the disease development mechanism of cholera, but not as
fully as the WT. More proficient disease development mechanisms
could be expected to be established by the VCUSM21P vaccine
candidate, referring to its prolonged survival capacity.
VCUSM21P live attenuated vaccine strain was only recoverable
in the stool of 2 of 4 rabbits for 1–2 days after a large large oral
inoculum with the first inoculation and not at all in any of the 4
rabbits after their second inoculation. However, it is anticipated
that attenuated strain will colonize the intestinal mucosal surface
for at least a few days in order to present many of the antigens that
may be associated with protection. The mice data are unin-
terruptable from the level of colonization since the mice were
sacrificed 16–18 hours after oral inoculation and therefore,
intestinal detection would not be consistent with colonization vs.
transient intestinal passage.
All four rabbits given the vaccination regime displayed no sign
of any residual diarrhoea, and these animals had developed
effective immunity against V. cholerae O139, evident from the high
level of antibodies against CTAB and LPS O139. Overall, they
also had the best known immunological correlation of protection
against cholera, the vibriocidal antibody, at elevated level. The
dose of vaccine used in this experiment has been rather similar to
that administrated previously [38] and, in the majority of animals
tested, induced substantial protective antibodies. Two immuniza-
tion regimens were able to greatly reduce WT bacterial replication
in the main site of bacterial burden, the mucus of the intestine.
Consistent with the high vibriocidal antibody titers, all animals
which had received the vaccine demonstrated no cholera symptom
after the WT challenge.
V. cholerae O139 is no longer exiting, but outbreak could happen
in future. Despite best efforts, a fully effective vaccine is still to be
obtained [44]. It is important to realize that VCUSM21P vaccine
carries the genes that encode the non-toxic A (A1) subunit and the
immuno-enhancing CTB molecules. The 7th amino acid of the
ctxA which is the arginine has been substituted with lysine (R7K),
and the 112th glutamate was substituted with glutamine (E112Q).
In some vaccine construction designs, CT has been made to lack
the ‘toxic’ ADP-ribosylating activity, by modifying the A1 subunit
However, a loss of toxicity in VCUSM21P has been matched with
a corresponding loss of its adjuvanticity, needing additional
immunostimulants for vaccination [45–47]. Besides vibriocidal
antibodies, IgA and IgG antibodies must have kept the animals
free from developing cholera.
In future study, mutant strain of hlyA and rec gene should be
created to minimize the mild diarrhea and likelihood of in field
recombination. Also immunological study could be extended by
including the detection of anti-O specific polysaccharide respons-
es, mucosal ASC responses, and responses to detect the induction
of memory cells.
Conclusion
In conclusion, we have expanded vaccine safety efforts and
constructed a new cholera vaccine, VCUSM21P, against V. cholerae
O139. This vaccine is suitably non-reactogenic and immunogenic
in vivo, and protects animals from lethal V. cholerae O139 challenge.
VCUSM21P could potentially help to reduce cholera disease
burdens around the world leading to elimination of childhood
mortality caused by V. cholerae O139 infection.
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